Buy & Sell Procter & Gamble Co (PG) – Procter & Gamble Co Price Today
Aura AI Summary
Key Stats
- $331.69BMarket Cap
- Consumer StaplesSector
- -15.48%3M Drawdown
- $357.16BEnterprise Value
- 2.99%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 127 daysTypical Hold Time
Procter & Gamble Co (PG) is currently valued at a market capitalization of $331.69B, with an enterprise value of $357.16B. Over the past 52 weeks, Procter & Gamble Co has traded between a low of $138.1 and a high of $169.89, highlighting its annual price range. Over the past three months, Procter & Gamble Co has recorded a drawdown of -15.48%, reflecting recent price volatility. Procter & Gamble Co offers a dividend yield of 2.99%, with the most recent dividend of $1.09 paid on 24 Apr 26. On average, investors hold Procter & Gamble Co for approximately 127 days, indicating typical investor behavior on the platform.
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Most Recent News
Yimutian requests Nasdaq hearing to avoid delisting over market value issues
Yimutian Inc., a Chinese agricultural digital service company, has formally requested a hearing with Nasdaq's Hering Panel after receiving a delisting notice due to not meeting minimum market value requirements. The hearing request halts any immediat...

Kevin Warsh sworn in as Fed Chair, first White House oath in 40 years, stocks may react.
Kevin Warsh officially becomes the Federal Reserve Chair on May 22, 2026, with his swearing-in ceremony hosted by President Donald Trump at the White House. This marks the first time in nearly 40 years that a Fed Chair has taken the oath of office at...

Liminatus Pharma to be delisted from Nasdaq for failing market value rules, plans to appeal.
Liminatus Pharma received a delisting notice from Nasdaq due to failure to meet minimum market value requirements for its listed securities and publicly held shares. The company was given until May 18, 2026, to regain compliance but did not meet the ...
